CLN-978 — Initial data
Q3 2026
In Q3 2026, the Company plans to share additional multi-dose regimen data.Source filing
CGEM biotech catalysts & pipeline
CULLINAN THERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
zipalertinib — Topline data
Late 2026
Taiho expects to obtain top-line results by the end of 2026.Source filing
CLN-049 — Interim data
Q4 2026
The Company plans to share an update from the dose escalation portion of the Phase 1 study in patients with relapsed/refractory AML or MDS in Q4 2026.Source filing
CLN-978 — Interim data
Q4 2026
The Company plans to report additional multi-dose regimen data for RA in Q3 2026 and SLE in Q4 2026Source filing
velinotamig — Interim data
Q4 2026
Additional multi-dose regimen data in patients with SLE from the Genrix Bio clinical trial in China expected to be shared in Q4 2026Source filing
zipalertinib — PDUFA
Feb 27
The Prescription Drug User Fee Act (PDUFA) target action date is February 27, 2027.Source filing